Population structure and HLA DRB1*1501 in the response of subjects with multiple sclerosis to first-line treatments

被引：32

作者：

Gross, Robert ^{[1
,2
]}

Healy, Brian C. ^{[2
,3
,4
]}

Cepok, Sabine ^{[5
]}

Chitnis, Tanuja ^{[2
,3
]}

Khoury, Samia J. ^{[2
,3
]}

Hemmer, Bernard ^{[5
]}

Weiner, Howard L. ^{[2
,3
]}

Hafler, David A. ^{[2
,3
,6
,7
]}

De Jager, Philip L. ^{[1
,2
,3
,7
]}

机构：

[1] Brigham & Womens Hosp, Program Translat NeuroPsychiat Gen, Dept Neurol, Boston, MA 02115 USA

[2] Harvard Univ, Sch Med, Boston, MA USA

[3] Brigham & Womens Hosp, Dept Neurol, Partners Multiple Sclerosis Ctr, Boston, MA 02115 USA

[4] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA

[5] Tech Univ Munich, Klinikum Rechts Isar, Dept Neurol, D-8000 Munich, Germany

[6] Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06510 USA

[7] Broad Inst, Program Med & Populat Genet, Cambridge, MA USA

来源：

JOURNAL OF NEUROIMMUNOLOGY | 2011年 / 233卷 / 1-2期

关键词：

Multiple sclerosis; Disease modifying treatment; Genetic; GLATIRAMER ACETATE; DOUBLE-BLIND; THERAPY; DISEASE; MULTICENTER; MS;

D O I：

10.1016/j.jneuroim.2010.10.038

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Using retrospectively collected outcome data for treatment naive subjects treated with either glatiramer acetate (GA) (n=332) or interferon beta (IFN beta) (n=424), we replicated the lack of a significant difference in efficacy between? these treatments. Further, for both treatments, we observed a decline in the hazard of a relapse over time, which may suggest the existence of subsets of subjects with differential responses to each treatment. The HLA DRB1*1501 allele explained some of this variation in event-free survival while on GA, and we found suggestive evidence that an IRF8 polymorphism influences event-free survival in IFN beta treated subjects. (C) 2010 Elsevier B.V. All rights reserved.

引用

页码：168 / 174

页数：7

共 27 条

[1]

[Anonymous], 2010, Survival Analysis Using SAS: A Practical Guide

[2]

[Anonymous], 2007, R LANG ENV STAT COMP

[3] Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications [J].

Arnon, R ;

Aharoni, R .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 :14593-14598

[4] Glatiramer acetate increases IL-1 receptor antagonist but decreases T cell-induced IL-1β in human monocytes and multiple sclerosis [J].

Burger, Danielle ;

Molnarfi, Nicolas ;

Weber, Martin S. ;

Brandt, Karim J. ;

Benkhoucha, Mahdia ;

Gruaz, Lyssia ;

Chofflon, Michel ;

Zamvil, Scott S. ;

Lalive, Patrice H. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (11) :4355-4359

[5] Efficacy of treatment of MS with IFNβ-1b or glatiramer acetate by monthly brain MRI in the BECOME study [J].

Cadavid, D. ;

Wolansky, L. J. ;

Skurnick, J. ;

Lincoln, J. ;

Cheriyan, J. ;

Szczepanowski, K. ;

Kamin, S. S. ;

Pachner, A. R. ;

Halper, J. ;

Cook, S. D. .

NEUROLOGY, 2009, 72 (23) :1976-1983

[6]

COMABELLA M, 2009, BRAIN

[7] European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis [J].

Comi, G ;

Filippi, M ;

Wolinsky, JS .

ANNALS OF NEUROLOGY, 2001, 49 (03) :290-297

[8] Cytometric profiling in multiple sclerosis uncovers patient population structure and a reduction of CD8low cells [J].

De Jager, Philip L. ;

Rossin, Elizabeth ;

Pyne, Saumyadipta ;

Tamayo, Pablo ;

Ottoboni, Linda ;

Viglietta, Vissia ;

Weiner, Mira ;

Soler, Dulce ;

Izmailova, Elena ;

Faron-Yowe, Lauren ;

O'Brien, Carmeline ;

Freeman, Sam ;

Granados, Susana ;

Parker, Alex ;

Roubenoff, Ronenn ;

Mesirov, Jill P. ;

Khoury, Samia J. ;

Hafler, David A. ;

Weiner, Howard L. .

BRAIN, 2008, 131 :1701-1711

[9] Integration of genetic risk factors into a clinical algorithm for multiple sclerosis susceptibility: a weighted genetic risk score [J].

De Jager, Philip L. ;

Chibnik, Lori B. ;

Cui, Jing ;

Reischl, Joachim ;

Lehr, Stephan ;

Simon, K. Claire ;

Aubin, Cristin ;

Bauer, David ;

Heubach, Juergen F. ;

Sandbrink, Rupert ;

Tyblova, Michaela ;

Lelkova, Petra ;

Havrdova, Eva ;

Pohl, Christoph ;

Horakova, Dana ;

Ascherio, Alberto ;

Hafler, David A. ;

Karlson, Elizabeth W. .

LANCET NEUROLOGY, 2009, 8 (12) :1111-1119

[10] Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci [J].

De Jager, Philip L. ;

Jia, Xiaoming ;

Wang, Joanne ;

de Bakker, Paul I. W. ;

Ottoboni, Linda ;

Aggarwal, Neelum T. ;

Piccio, Laura ;

Raychaudhuri, Soumya ;

Tran, Dong ;

Aubin, Cristin ;

Briskin, Rebeccah ;

Romano, Susan ;

Baranzini, Sergio E. ;

McCauley, Jacob L. ;

Pericak-Vance, Margaret A. ;

Haines, Jonathan L. ;

Gibson, Rachel A. ;

Naeglin, Yvonne ;

Uitdehaag, Bernard ;

Matthews, Paul M. ;

Kappos, Ludwig ;

Polman, Chris ;

McArdle, Wendy L. ;

Strachan, David P. ;

Evans, Denis ;

Cross, Anne H. ;

Daly, Mark J. ;

Compston, Alastair ;

Sawcer, Stephen J. ;

Weiner, Howard L. ;

Hauser, Stephen L. ;

Hafler, David A. ;

Oksenberg, Jorge R. .

NATURE GENETICS, 2009, 41 (07) :776-U26

← 1 2 3 →